You are here

Glyxambi

CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes

CP Wire

Mon, 07/2/18 - 10:02 am

Boehringer Ingelheim

CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes

Mon, 07/2/18 - 09:26 am

Boehringer Ingelheim

J&J's Invokana fends off new SGLT2 rivals to hit $278M in Q1

Fierce Pharma Marketing

Wed, 04/15/15 - 09:28 am

SGLT2 inhibitor

Boehringer Ingelheim

FDA approves Boehringer-Lilly drug for type-2 diabetes patients

Yahoo/Reuters

Mon, 02/2/15 - 11:01 am

Boehringer Ingelheim

type 2 diabetes